After splittingThe first quarterly earnings report was released after,GE Healthcare fell 14.3% on April 30, 2024, closing at $76.24. The stock has dropped 11.6% over the past five trading days and declined 16.1% for the entire month of April.

GE HealthcareAnnounced, compared with the first quarter of last year,The organic growth in the first quarter of this year was basically flat, with revenue decreasing by 1% year-over-year from $4.7 billion in 2023 to $4.65 billion in 2024, leading to itsStock PriceDown 14.3%.

Although the decline was relatively large, the market still showed a positive attitude. On April 30, 2024, GE Healthcare's trading volume was $1.129 billion, ranking 47th in the U.S. stock market that day. The trading volume increased by 193.75% compared to the previous day, with a total of 14.4336 million shares traded.

The company's net income for the first quarter was $374 million, compared to $372 million in the same period last year. The adjusted EBIT for the first quarter of 2024 was $681 million, while it was $664 million in the first quarter of 2023.

Generated from operating activitiesCash flow was $419 million, a decrease of $49 million from the previous year, and free cash flow was $274 million, a decrease of $51 million from 2023.The company repaid $150 million of debt in the first month of this year.

Diluted earnings per share (EPS) were $0.81, compared to $0.41 in the same period last year, and adjusted earnings per share were $0.90, compared to $0.85 in the same period last year.

GE Healthcare President and CEO Peter Arduini stated, "We made good progress on our priorities for 2024 in the first quarter. While expanding our margins, we continue to invest in innovation to meet the evolving needs of our customers and patients. This is reflected in our healthy backlog, order growth, and positive book-to-bill ratio."

GE Healthcare also reaffirmed its full-year 2024 guidance.Including organic revenue growth of approximately 4% year-over-year.Adjusted EBIT margin between 15.6% and 15.9%, representing an increase of 50 to 80 basis points compared to the adjusted EBIT margin of 15.1% in 2023. The adjusted effective tax rate (ETR) is between 23% and 25%. Adjusted earnings per share are in the range of $4.20 to $4.35, reflecting a growth of 7% to 11% compared to the adjusted earnings per share of $3.93 in 2023.

Currently, institutions are relatively optimistic about the development trend of GE Healthcare. On May 1, Mizuho maintained a "Buy" rating for GE Healthcare, with a latest target price of $105.00.

As one of the largest medical imaging manufacturers globally, GE Healthcare continues to expand its layout, broaden its business scope, and consolidate its market position through acquisitions and collaborations. In particular, it is increasing investment in the fields of imaging and artificial intelligence.

Launch Revolution RT

Recently, at the European Society for Radiotherapy and Oncology (ESTRO) 2024 Annual Conference,GE Healthcare announced the launch of Revolution RT, a computed tomography product for radiation therapy focused on oncology., aiming to improve imaging accuracy.

The company also launched an updated and artificial intelligence (AI)-enhanced version of its intelligent radiation therapy platform (iRT), which is connected to the Spectronic magnetic resonance imaging planner.

Acquisition of MIM Software

Recently, GE Healthcare has completed the acquisition of MIM Software, a provider of artificial intelligence and medical image analysis.

Data shows that MIM Software was founded in 2003, with its headquarters located in Cleveland, USA. It focuses on providing AI-based software, covering multiple medical fields such as radiation oncology, molecular radiotherapy, diagnostic imaging, and urology.The company's products are widely used in imaging centers, hospitals, professional clinics, and research institutions worldwide.

GE Healthcare Plans to Integrate MIM Software's Innovative Solutions into Its Advanced Visualization Products to Drive the Application of Digital Technologies, Including AI-Based Lesion Segmentation and Target Area Delineation, Dose Analysis in Radiation Therapy, Across All Stages of Disease Diagnosis and Treatment — Especially in the Rapidly Growing Fields of Radiology, Nuclear Medicine Molecular Imaging, and Radiation Oncology.

Invest in Laza Medical

In December 2023, GE Healthcare participated in the $36 million (approximately RMB 236 million) Series A financing of Laza Medical, a subsidiary of the well-known medical incubator Shifamed. It is reported that,Laza Medical is developing a cardiac interventional imaging solution supported by AI and state-of-the-art robotic technology.

Collaboration with Sectra

In November 2023, a partnership was reached with Sectra, an international giant in medical imaging IT. Both parties will work together to achieve seamless integration of their products, providing more efficient medical imaging diagnostic solutions.

According to the agreement,Sectra will integrate its developed radiology imaging solutions into GE Healthcare's AW Family advanced visualization applications.This integration will cover every aspect from coordination and diagnosis to report generation and results distribution, supporting clinicians with precision care solutions at every step of the care pathway, improving work efficiency, saving time, and reducing the workload of healthcare professionals.

Strategic Cooperation Reached with Atomic High-Tech

In the Chinese market, in February 2024, GE Healthcare China announced a strategic partnership with Atom High-Tech, a subsidiary of China Isotope & Radiation Corporation.Both parties will pool their resources to launch innovative cooperation in the field of nuclear medicine diagnostic drugs, jointly promoting high-quality development for the nuclear medicine industry and accelerating the implementation of precision medicine based on nuclear medicine innovation. This also marks another significant milestone in GE Healthcare's China strategy of "comprehensive localization, boundaryless innovation, and win-win cooperation."

As a global leading medical device enterprise, GE Healthcare has redefined the standard of patient care in recent years by integrating respective strengths, bringing positive impacts to healthcare providers and patients. Since its independent listing, the company has also achieved strong growth in 2023 with a brand-new status, and the first quarter of 2024 is currently in an adjustment phase. How will GE Healthcare achieve its predetermined goals for 2024? Instrumentation will continue to follow up.

END

 

More exciting content

Welcome to follow WeChat Video Channel

Instrument Family

Related Reading

Tap for more!

Double Celebration! United Imaging Healthcare's 2023 Annual Revenue Grows by 23.52%, 5T Approved by FDA 510(k)

Asia's First 15T Translational Medicine Imaging Platform Launched in China

World's Only, "National Heavyweight" Lands

The King of Hemodialysis, 2.2 Million Devices Recalled at Level One

The King of M&A, Investing in the Largest Single Project in China

Just now, the SureRobot® robot was ranked on this important list.

Mindray: Joining Hands to Create a Blueprint for the Development of Chinese Surgery

After $17 Billion Acquisition, Medical Device Giant Announces More Layoffs and Plant Closures

FDA Warning: Imaging Giant's China Factory Violates Regulations

Foreign Ministry Responds: EU Launches Investigation into Equipment Procurement from China

For the First Time, Medtronic Appoints This Senior Executive

BusinessBusiness cooperation email: qxzj@landianyiliao.com